Furthermore, IMPC and IDC patients also differed with regard to molecular subtype as indicated by combined ER/PR/HER2 status (p<0.001); the incidence of triple negative breast cancer (TNBC) was lower in IMPC (2, 1.4%) than in IDC (141, 21.8%) patients, while luminal A, luminal B, and HER-2 overexpression occurred more frequently in IMPC than in IDC patients. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.